Anonymous ID: ec2222 Nov. 18, 2022, 11:49 a.m. No.17787834   🗄️.is 🔗kun


Pennsylvania lawmakers voted on Wednesday to impeach Philadelphia district attorney Larry Krasner (D.), capping a months-long campaign to remove the George Soros-backed prosecutor on the heels of a historic murder wave.

Anonymous ID: ec2222 Nov. 18, 2022, 11:53 a.m. No.17787853   🗄️.is 🔗kun


Breaking: RN Shares the most powerful and horrifying testimony I’ve heard since the vaccine rollout started and she corroborates her story with internal hospital emails on The Highwire.


Full interview (



Anonymous ID: ec2222 Nov. 18, 2022, 11:55 a.m. No.17787858   🗄️.is 🔗kun



Anonymous ID: ec2222 Nov. 18, 2022, 11:56 a.m. No.17787864   🗄️.is 🔗kun   >>7898


Disgraced FTX Founder Donated To Six RINOs

Who Voted To Impeach Trump


Gateway Pundit, by Anthony Scott


Original Article


Posted By: Hazymac, 11/18/2022 9:33:45 AM


As most are well aware by now, the disgraced founder of FTX Sam Bankman-Fried was the Democrat party’s second-largest donor just behind George Soros. As reported by The Gateway Pundit, in the 2020 presidential election, Bankman-Fried dished millions to the Biden campaign and followed it up by handing out over $40 million dollars to democrats in the 2022 primaries and midterms. Forbes reported last year that Bankman-Fried also donated to six RINOs who voted to impeach President Trump. (Snip) As previously reported, Bankman-Fried’s balance sheet contained an asset worth over $7 million called “TrumpLose.” CEO of Citadel Ken Griffin, has also taken a look at the FTX’s

Anonymous ID: ec2222 Nov. 18, 2022, 11:57 a.m. No.17787868   🗄️.is 🔗kun


If You Are In Arizona, Report Election Crime At SAVEAZNOW.COM

Anonymous ID: ec2222 Nov. 18, 2022, noon No.17787885   🗄️.is 🔗kun   >>7891


The Media’s ‘Strange New Respect’

for Mike Pence


The American Spectator, by Francis P. Sempa


Original Article


Posted By: WhamDBambam, 11/18/2022 9:00:49 AM


Republicans, especially those running for president in 2024, know how to get treated “respectfully” by the mainstream media: denounce or at least distance yourself from former President Donald Trump. Former Vice President Mike Pence has learned that lesson and is being treated much better than he previously was by the media.

Anonymous ID: ec2222 Nov. 18, 2022, 12:12 p.m. No.17787914   🗄️.is 🔗kun



Ultomiris Approved to Treat Rare Blood Disorder


December 21, 2018 – The U.S. FDA has approved UltomirisTM (ravulizumab), manufactured by Alexion Pharmaceuticals, to treat adult patients who have paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.


An acquired disorder, PNH causes blood clots (thrombosis), impaired bone marrow function, and the destruction of red blood cells (leading to hemolytic anemia). The median age of diagnosis is 30-45 years, but the disease can occur in children and adolescents. Up to 30% of patients with PNH have previously had aplastic anemia. Median survival following diagnosis is 10 years.


Ultomiris treats PNH by helping to prevent the destruction of blood cells. In a clinical study, it was found to have similar efficacy to the current standard of treatment, Alexion’s Soliris® (eculizumab).


Unlike Soliris, Ultomiris requires administration only once every eight weeks for maintenance therapy.Soliris must be administered once every two weeks under its PNH indication. Patients treated with Ultomiris can begin the maintenance dose just two weeks after an initial loading dose; those treated with Soliris are titrated up from a starting dose, receiving weekly injections for five weeks before moving to maintenance therapy.


A black box warning advises that life-threatening meningococcal infections/sepsis have occurred in patients treated with Ultomiris. Patients should be immunized against meningococcal infection at least two weeks prior to beginning treatment, and should be monitored for signs of infection. Soliris carries a similar black box warning. Both Soliris and Ultomiris are available only through a Risk Evaluation and Mitigation Strategy (REMS) program.


Ultomiris is expected to launch in 2019 at an estimated average annual cost of $458,000 per patient – approximately 10% less per year than Soliris.


The FDA approved Soliris to treat paroxysmal nocturnal hemoglobinuria in 2007. It initially earned Alexion nearly $1.1 billion a year; additional approvals for other rare diseases with similar biological dysfunctions have increased annual sales to $3.5 billion. At a cost of more than $500,000 per year, Soliris is one of the most expensive drugs in the world. And rightfully so: Not only is it the first of its kind, but it is extremely effective at treating certain rare diseases once thought to be fata


When Ultomiris finally makes its way onto the market, it will be only slightly less expensive than Soliris, costing $458,000 per year. Both drugs must be administered in a hospital or doctor’s office by intravenous infusion.